Related references
Note: Only part of the references are listed.Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2020)
Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease
Siddhartha Jaiswal et al.
NATURE REVIEWS CARDIOLOGY (2020)
Vaccination Strategies and Immune Modulation of Atherosclerosis
Jan Nilsson et al.
CIRCULATION RESEARCH (2020)
Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas
Alma Zernecke et al.
CIRCULATION RESEARCH (2020)
Role of the adaptive immune system in atherosclerosis
Klaus Ley
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
Colchicine in Patients with Chronic Coronary Disease
Stefan M. Nidorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chemokines as Therapeutic Targets in Cardiovascular Disease The Road Behind, The Road Ahead
Heidi Noels et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Novel Antiatherosclerotic Therapies
Peter Libby et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Targeting the Immune System in Atherosclerosis
Tian X. Zhao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
From Focal Lipid Storage to Systemic Inflammation JACC Review Topic of the Week
Peter Libby et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The role of B cells in atherosclerosis
Andrew P. Sage et al.
NATURE REVIEWS CARDIOLOGY (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker et al.
LANCET (2018)
Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial
Tian Xiao Zhao et al.
BMJ OPEN (2018)
Interleukin-1 Beta as a Target for Atherosclerosis Therapy Biological Basis of CANTOS and Beyond
Peter Libby
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker et al.
LANCET (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Jose J. Fuster et al.
SCIENCE (2017)
Boosting Inflammation Resolution in Atherosclerosis The Next Frontier for Therapy
Gabrielle Fredman et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
Paul M. Ridker
EUROPEAN HEART JOURNAL (2016)
A Test in Context High-Sensitivity C-Reactive Protein
Paul M. Ridker
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Inflammation and its Resolution as Determinants of Acute Coronary Syndromes
Peter Libby et al.
CIRCULATION RESEARCH (2014)
Thematic Review Series: Living History of Lipids In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis
Daniel Steinberg
JOURNAL OF LIPID RESEARCH (2013)
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Stefan M. Nidorf et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
A Randomized Trial of Colchicine for Acute Pericarditis
Massimo Imazio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen A Phase IIb Randomized, Placebo-Controlled Trial
Paul M. Ridker et al.
CIRCULATION (2012)
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Paul M. Ridker et al.
AMERICAN HEART JOURNAL (2011)
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data
Frances Wensley et al.
BRITISH MEDICAL JOURNAL (2011)
Clinical implications of inflammation for cardiovascular primary prevention
Peter Libby et al.
EUROPEAN HEART JOURNAL (2010)
The Discovery of Cellular Immunity in the Atherosclerotic Plaque
Goran K. Hansson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
Paul Elliott et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
Paul M. Ridker
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Paul M. Ridker et al.
LANCET (2009)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial
David A. Morrow et al.
CIRCULATION (2006)
Atherosclerosis research from past to present - on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow
Christina Mayerl et al.
VIRCHOWS ARCHIV (2006)
C-reactive protein levels and outcomes after statin therapy
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
An interpretive history of the cholesterol controversy: part I
D Steinberg
JOURNAL OF LIPID RESEARCH (2004)
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein - Rationale and design of the JUPITER trial
PM Ridker
CIRCULATION (2003)
Cholesterol and atherosclerosis
P Libby et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2000)
Share Paper
